Heart failure & cardiomyopathiesSecondary analysis
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis
- Secondary analysis of the ATTRibute-CM randomised trial
- in vitro analysis
Authors' conclusion
Acoramidis is a near-complete stabilizer of wild type and variant TTR.
Study context
- Population
- Patients with wild type or variant ATTR-CM
- Participants
- 234 vs 34
- Comparison
- Acoramidis vs placebo plus tafamidis
- Acoramidisn = 234
- Placebo plus tafamidisn = 34reference
- Primary endpoint
- TTR stabilizing effect and magnitude of sTTR increase
- Follow-up
- Month 30
Primary result
As reported in the abstract
TTR stabilization
| Group | Western blot | Fluorescent probe exclusion |
|---|---|---|
| Acoramidis | 90.2% [n = 83] | 99.7% [n = 71] |
| Placebo plus tafamidis | 60.6% [n = 6] | 68.0% [n = 4] |
Further findings
In vitro TTR stabilization (acoramidis 10 μM vs tafamidis 16-26 μM)
- Acoramidis more effective TTR stabilizer than tafamidis across all 51 participant samples (17 unique variants)
Original publication
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis. JACC CardioOncol. doi:10.1016/j.jaccao.2026.04.006
Summarised from the published abstract; every number is checked against it